scispace - formally typeset
C

Christian Weyer

Researcher at Amylin Pharmaceuticals

Publications -  103
Citations -  18814

Christian Weyer is an academic researcher from Amylin Pharmaceuticals. The author has contributed to research in topics: Insulin & Pramlintide. The author has an hindex of 59, co-authored 103 publications receiving 18015 citations. Previous affiliations of Christian Weyer include National Institutes of Health.

Papers
More filters
Journal ArticleDOI

40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004.

M Veitenhansl, +5467 more
- 01 Aug 2004 - 
Journal ArticleDOI

Pancreatic Polypeptide Is Involved in the Regulation of Body Weight in Pima Indian Male Subjects

TL;DR: Evidence is provided that, even within the physiological range, PP contributes to the regulation of energy balance in humans, however this contribution appears to be more complex than anticipated because of the opposite effect of fasting and postprandial PP on the risk of future weight gain.
Journal ArticleDOI

Parasympathetic blockade attenuates augmented pancreatic polypeptide but not insulin secretion in Pima Indians

TL;DR: In this paper, the effect of PNS blockade in 17 Caucasian (aged 35 +/- 8 years, body fat 23 +/- 7% [mean +/- SD]) and 17 Pima Indian males with normal glucose tolerance was examined, where a primed infusion of atropine was administered for 120 min at the following doses: 0, 2.5, 5, and 10 micro g.
Journal ArticleDOI

Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy.

TL;DR: If confirmed in ongoing translational clinical research studies, these findings may provide a physiological rationale for a novel, integrated neurohormonal approach to pharmacotherapy for obesity.
Journal ArticleDOI

Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.

TL;DR: Two hormones still in development are candidates for pharmacologic intervention, have novel modes of action (some centrally mediated), and show great promise in addressing some of the unmet needs of current diabetes management.